We retrospectively reviewed TI-GI CMV patients diagnosed at Songklanagarind Hospital, a tertiary care university hospital and a referral center in Southern Thailand, between July 2005 and March 2020. We identified all adult (age of at least 18 years) patients with histopathological proven TI-GI CMV during the study period from the Division of Pathology database. The information regarding demographic data, comorbidities, medication usage, clinical presentation, endoscopic findings, laboratory data, treatments, and outcomes were obtained from an institutional Hospital Information System (HIS). The characteristics and outcomes of the patients were compared between immunocompromised and immunocompetent groups as the definition described in the next section. This study was approved by the Human Research Ethics Committee (HREC) of the Faculty of Medicine, Prince of Songkla University.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.